VKVictor A. Kehinde

Victor A. Kehinde

*This is an algorithmically generated author record based on publicly available information.

Victor A. Kehinde has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS-mutant neuroblastoma

    by Ronald D. Hill, Krista M. Dalton, Richard Kurupi, Yanli Xing, Jamie M. Slaughter, Jane Roberts, Victor A. Kehinde, Kun Zhang, Bin Hu, Li Wang, et al.

    Neuroblastoma (NB) is the most common extracranial solid tumor in children. Patients with relapsed or refractory (R/R) high-risk (HR) NB exhibit poor outcomes despite intensive multimodal therapy. Although MAPK pathway activation is prominent in HRNB, FDA-approved MEK inhibitors and KRAS G12C inhibitors have shown limited preclinical single-agent activity in HRNB. Daraxonrasib (RMC-6236), a potent and selective RAS(ON) inhibitor, has demonstrated activity in preclinical models and early-phase clinical trials of RAS-mutant adult cancers. A subset of R/R HRNB tumors harbors diverse RAS mutations, providing a rationale for investigating RMC-6236 in this setting. Here, we evaluated the therapeutic efficacy and effects of oncogenic signaling modulation of RMC-6236 across NB models with RAS pathway activation. As a single agent, RMC-6236 significantly reduced cell viability, suppressed downstream MAPK signaling, increased expression of the MAPK pathway effector BIM, and induced cell death in RAS-mutant NB models as well as in NF1-mutant NB models. In vivo, RMC-6236 demonstrated on-target activity, significantly inhibited tumor growth, and extended survival in RAS-mutant HRNB mouse models. Furthermore, RMC-6236 induced BIM upregulation and promoted BIM:BCL-2 complexes in RAS-mutant NB. As such, the BCL-2 inhibitor venetoclax further potentiated RMC-6236-mediated killing by disrupting these complexes. Together, these findings identify RMC-6236 as a promising targeted therapy for RAS-mutant NB and support its clinical investigation, both as a single agent and in combination with venetoclax, in this patient population.

  • Open Access

    Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma

    by Konstantinos V. Floros, Carter K. Fairchild, Jinxiu Li, Kun Zhang, Jane L. Roberts, Richard Kurupi, Durga Paudel, Yanli Xing, Bin Hu, Vita Kraskauskiene, et al.

    Synovial Sarcoma (SS) is driven by the SS18::SSX fusion oncoprotein and is ultimately refractory to therapeutic approaches. SS18::SSX alters ATP-dependent chromatin remodeling BAF (mammalian SWI/SNF) complexes, leading to the degradation of canonical (cBAF) complexes and amplified expression of SS18::SSX-containing non-canonical BAF (ncBAF or GBAF) complexes that drive an SS-specific transcription program and tumorigenesis. We demonstrate that SS18::SSX activates the SUMOylation program. The small molecule SUMOylation inhibitor, TAK-981, de-SUMOylates the cBAF/PBAF component, SMARCE1, stabilizing and restoring cBAF on chromatin, shifting SS models away from SS18::SSX-driven transcription. The result is DNA damage, cell death and tumor inhibition across both human and mouse SS tumor models. TAK-981 synergizes with cytotoxic chemotherapy through increased DNA damage, leading to tumor regression. Targeting the SUMOylation pathway in SS restores cBAF complexes and blocks the SS18::SSX transcriptome, identifying an unappreciated role of SUMOylation in SS and a subsequent therapeutic vulnerability.